Le Lézard
Classified in: Health, Science and technology
Subject: Sales

Biogennix Reports Record Year for Sales in 2021


Irvine-based Biogennix, an advanced osteobiologics company that develops, manufactures, and distributes proprietary bone grafting products used for bone fusion procedures, announced today that 2021 was the best sales year in company history. The company also announced that the third and fourth quarters of 2021 were the best performing six months for the company to date.

"Despite challenges faced by the industry over the past two years due to the global pandemic, Biogennix has been able to maintain our momentum throughout 2021, and thanks to a particularly strong second half of 2021, we were able to exceed expectations," said Chris MacDuff, Biogennix's CEO. "Our continued growth last year was also fueled by the launch of our first advanced bone graft strip product, Agilon® Strip, which expands our TrelCor-based Agilon product family."

MacDuff mentioned that Biogennix also saw increasing sales for its newest moldable bone graft product, Agilon Moldable, particularly in the foot & ankle surgery market, due to its advanced TrelCor material properties and best-in-class handling. The company also continued to see consistently strong growth of Agilon Moldable in the spine market segment.

"It was rewarding to celebrate the tenth anniversary of our first clinical case last year while also experiencing our strongest growth year yet," added MacDuff. "We look forward to further growth in 2022, with several new product launches and exciting initiatives being introduced throughout the year."

Biogennix's proprietary TrelCor technology is a bioactive synthetic material engineered to jumpstart patients' natural healing processes. TrelCor technology uniquely combines multiple cutting-edge scientific principles into one advanced material that actively promotes cellular healing and new bone formation. Biogennix proprietary bone graft technologies have been implanted over 50,000 times since the initial market release in 2011.

Biogennix designs, manufactures and distributes all of its products from its Irvine facilities.

Biogennix® is a fully-integrated advanced osteobiologics company headquartered in Irvine which develops, manufactures, and distributes proprietary bone grafting products used in bone fusion procedures. Biogennix is committed to advancing technology behind next-generation bone grafting solutions, delivering outstanding quality with exceptional value, and customer-focused excellence. Learn more at biogennix.com.


These press releases may also interest you

at 13:44
CellFE Inc., a life sciences tools company with a novel microfluidics-based cellular engineering platform, announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting,...

at 13:33
EHN Canada proudly announces a significant regional expansion of EHN Bellwood's legacy in pioneering addiction and mental health treatment centres....

at 13:30
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners CARBIOS' first plant is also a world first using revolutionary enzymatic depolymerization technology, marking a major step forward in the...

at 13:25
CBL-514 is the first product to treat cellulite at the raised areas.Currently, there is no effective and safe cellulite treatment on the market. The global market for cellulite treatment is estimated to expand to $7.37 billion in 2034.CBL-0201EFP...

at 13:15
The Board of Governors of the Canadian Memorial Chiropractic College (CMCC) is delighted to announce the appointment of Dr. Christine Bradaric-Baus as its next President, effective July 1, 2024, following the retirement of President...

at 13:13
Hoag is proud to announce the recruitment of cancer researchers and subspecialized oncologists Monica Mita, M.D., M.Sc., Mh.D.S., and Alain Mita, M.D., M.Sc., to the Hoag Family Cancer Institute....



News published on and distributed by: